Trusted Resources: Education
Scientific literature and patient education texts
Carpal Tunnel Syndrome May Triple Your Risk of Developing Stiff Heart Syndrome
source: https://www.verywellhealth.com/carpal-tunnel-risk-of-stiff-heart-syndrome-8673860
year: 2024
summary/abstract:According to a recent study, carpal tunnel syndrome might be an early sign of transthyretin amyloid cardiomyopathy (ATTR-CM), a type of cardiac amyloidosis known as “stiff heart syndrome.”
The research, published in Mayo Clinic Proceedings, found that patients with carpal tunnel syndrome had a higher prevalence of amyloid deposits in their tissue. The link was especially true for people having carpal tunnel release surgery.1 As a result, people with carpal tunnel have three times the risk of developing amyloidosis compared to those without carpal tunnel syndrome. They also have a 13% greater risk of heart failure.
“This link is crucial, as it suggests that carpal tunnel syndrome could serve as an early warning sign for cardiac amyloidosis, potentially allowing for earlier diagnosis and intervention to prevent severe cardiac complications,” Pankaj Arora, MD, the senior author of the study and an associate professor of medicine in the Division of Cardiovascular Disease at the University of Alabama at Birmingham, told Verywell.
Here’s what experts want you to know about protecting your joints and heart if you have carpal tunnel syndrome.
DOI: July 9th 2024Related Content
-
Clinical Trials: Benefits, Risks, and SafetyYou may ask yourself, "Why should I tr...
-
Multiple Myeloma and Amyloidosis Program, Cedars-SinaiThe Multiple Myeloma and Amyloidosis pro...
-
Yvonne S. Eisele, PhDYvonne S. Eisele is Assistant Professor ...
-
Doctors Making Progress in Treating AmyloidosisAmyloidosis is a rare condition that use...
-
Taking Your Next Steps: Life Following hATTR Amyloidosis DiagnosisBeing diagnosed with hATTR amyloidosis...
-
Alnylam Reports Positive Topline 18-Month Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR A...Alnylam Pharmaceuticals, Inc., the leadi...
-
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual MeetingAkcea Therapeutics, Inc. (NASDAQ: AKCA),...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.